Heart transplantation criteria: Difference between revisions
Ifrah Fatima (talk | contribs) |
Ifrah Fatima (talk | contribs) |
||
| Line 10: | Line 10: | ||
===Cardiopulmonary stress testing to guide transplant listing=== | ===Cardiopulmonary stress testing to guide transplant listing=== | ||
Exercise capacity as assessed by VO2max is a dynamic objective variable that assesses cardiac reserve and peripheral adaptations to a reduced cardiac output much more accurately than NYHA classification. | "Exercise capacity as assessed by VO2max is a dynamic objective variable that assesses cardiac reserve and peripheral adaptations to a reduced cardiac output much more accurately than NYHA classification." <ref name="pmid25132979">{{cite journal| author=Alraies MC, Eckman P| title=Adult heart transplant: indications and outcomes. | journal=J Thorac Dis | year= 2014 | volume= 6 | issue= 8 | pages= 1120-8 | pmid=25132979 | doi=10.3978/j.issn.2072-1439.2014.06.44 | pmc=4133547 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25132979 }} </ref> | ||
The following cutoff values of peak oxygen consumption (VO2) are used to guide listing in various cases- | * A maximal cardiopulmonary exercise test is defined as one with a respiratory exchange ratio (RER) > 1.05 and achievement of an anaerobic threshold on optimal pharmacologic therapy. | ||
The following cutoff values of peak oxygen consumption (VO2) are used to guide listing in various cases- <ref name="MehraCanter2016">{{cite journal|last1=Mehra|first1=Mandeep R.|last2=Canter|first2=Charles E.|last3=Hannan|first3=Margaret M.|last4=Semigran|first4=Marc J.|last5=Uber|first5=Patricia A.|last6=Baran|first6=David A.|last7=Danziger-Isakov|first7=Lara|last8=Kirklin|first8=James K.|last9=Kirk|first9=Richard|last10=Kushwaha|first10=Sudhir S.|last11=Lund|first11=Lars H.|last12=Potena|first12=Luciano|last13=Ross|first13=Heather J.|last14=Taylor|first14=David O.|last15=Verschuuren|first15=Erik A.M.|last16=Zuckermann|first16=Andreas|title=The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update|journal=The Journal of Heart and Lung Transplantation|volume=35|issue=1|year=2016|pages=1–23|issn=10532498|doi=10.1016/j.healun.2015.10.023}}</ref> | |||
* Patients intolerant of a β-blocker- Peak Vo 2 of ≤ 14 ml/kg/min | * Patients intolerant of a β-blocker- Peak Vo 2 of ≤ 14 ml/kg/min | ||
* In the presence of a β-blocker- peak Vo 2 of ≤ 12 ml/kg/min | * In the presence of a β-blocker- peak Vo 2 of ≤ 12 ml/kg/min | ||
Revision as of 12:23, 7 June 2020
|
Heart transplantation Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Heart transplantation criteria On the Web |
|
American Roentgen Ray Society Images of Heart transplantation criteria |
|
Risk calculators and risk factors for Heart transplantation criteria |
Editor(s)-in-Chief: C. Michael Gibson, M.S., M.D.; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [1]
Criteria for Cardiac Transplantation
While assessment of the indications and contraindications are important first steps in evaluating the appropriateness for cardiac transplantation, the prognosis of a patient with and without transplantation is critical in making the final determination as to whether a patient is suitable for cardiac transplantation. Discussed below are criteria that are used based upon the estimation of the patient's prognosis. The pre-transplantation evaluation includes-
Cardiopulmonary stress testing to guide transplant listing
"Exercise capacity as assessed by VO2max is a dynamic objective variable that assesses cardiac reserve and peripheral adaptations to a reduced cardiac output much more accurately than NYHA classification." [1]
- A maximal cardiopulmonary exercise test is defined as one with a respiratory exchange ratio (RER) > 1.05 and achievement of an anaerobic threshold on optimal pharmacologic therapy.
The following cutoff values of peak oxygen consumption (VO2) are used to guide listing in various cases- [2]
- Patients intolerant of a β-blocker- Peak Vo 2 of ≤ 14 ml/kg/min
- In the presence of a β-blocker- peak Vo 2 of ≤ 12 ml/kg/min
- Young patients (< 50 years) and women- percent of predicted (≤ 50%) peak Vo 2 and using alternate standards in conjunction it
- Sub-maximal cardiopulmonary exercise test (RER < 1.05)- use of ventilation equivalent of carbon dioxide (Ve/Vco 2) slope of > 35
- Obese (body mass index [BMI] > 30 kg/m 2) patients- adjusting peak Vo 2 to lean body mass may be considered. A lean body mass–adjusted peak Vo 2 of < 19 ml/kg/min is used for listing.
Use of Heart Failure prognosis scores
1. Seattle Heart Failure Model (SHFM) - An estimated 1-year survival as calculated by the Seattle Heart Failure Model (SHFM) of < 80%
The factors considered in this model are-
- age
- sex
- NYHA class
- weight
- ejection fraction
- blood pressure
- medications,
- few laboratory values
SHFM model has also incorporated the impact of newer HF therapies on survival, including ICDs and CRT.
2. Heart Failure Survival Score (HFSS) in the high/medium risk range
The predictors of survival in the HFSS include: [1]
- Presence or absence of coronary artery disease
- Resting heart rate
- Left ventricular ejection fraction
- Mean arterial blood pressure
- Presence or absence of an intraventricular conduction delay on ECG
- Serum sodium
- VO2max.
3. Index for Mortality Prediction After Cardiac Transplantation (IMPACT) score
Listing patients solely on the criteria of heart failure survival prognostic scores should not be performed. [2]
Role of Diagnostic Right Heart Catheterization
- Right heart catheterization (RHC) should be performed on all adult candidates in preparation for listing for cardiac transplantation and periodically until transplantation.
Donor Criteria
- Brain death declared
- Age <45 (special exceptions)
- No pre-existent heart disease
- Few coronary artery disease risk factors
- No untreated acute infections
- No systemic malignancy
- No cardiac trauma
- Normal ECG
- Normal echocardiogram
- Negative HIV and Hepatitis screen
References
- ↑ 1.0 1.1 Alraies MC, Eckman P (2014). "Adult heart transplant: indications and outcomes". J Thorac Dis. 6 (8): 1120–8. doi:10.3978/j.issn.2072-1439.2014.06.44. PMC 4133547. PMID 25132979.
- ↑ 2.0 2.1 Mehra, Mandeep R.; Canter, Charles E.; Hannan, Margaret M.; Semigran, Marc J.; Uber, Patricia A.; Baran, David A.; Danziger-Isakov, Lara; Kirklin, James K.; Kirk, Richard; Kushwaha, Sudhir S.; Lund, Lars H.; Potena, Luciano; Ross, Heather J.; Taylor, David O.; Verschuuren, Erik A.M.; Zuckermann, Andreas (2016). "The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update". The Journal of Heart and Lung Transplantation. 35 (1): 1–23. doi:10.1016/j.healun.2015.10.023. ISSN 1053-2498.